298 related articles for article (PubMed ID: 21817854)
21. Strategies to improve the effect of vaccination in the elderly: the vaccine producer's perspective.
Guy B
J Comp Pathol; 2010 Jan; 142 Suppl 1():S133-7. PubMed ID: 19897207
[TBL] [Abstract][Full Text] [Related]
22. Transcutaneous immunization: an emerging route of immunization and potent immunostimulation strategy.
Hammond SA; Guebre-Xabier M; Yu J; Glenn GM
Crit Rev Ther Drug Carrier Syst; 2001; 18(5):503-26. PubMed ID: 11763499
[TBL] [Abstract][Full Text] [Related]
23. [New routes of administration: epidermal, transcutaneous mucosal ways of vaccination].
Denis F; Alain S; Ploy MC
Med Sci (Paris); 2007 Apr; 23(4):379-85. PubMed ID: 17433227
[TBL] [Abstract][Full Text] [Related]
24. Devices for intradermal vaccination.
Kis EE; Winter G; Myschik J
Vaccine; 2012 Jan; 30(3):523-38. PubMed ID: 22100637
[TBL] [Abstract][Full Text] [Related]
25. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers.
Li N; Peng LH; Chen X; Nakagawa S; Gao JQ
Vaccine; 2011 Aug; 29(37):6179-90. PubMed ID: 21740946
[TBL] [Abstract][Full Text] [Related]
26. Intradermal naked plasmid DNA immunization: mechanisms of action.
Elnekave M; Furmanov K; Hovav AH
Expert Rev Vaccines; 2011 Aug; 10(8):1169-82. PubMed ID: 21854310
[TBL] [Abstract][Full Text] [Related]
27. Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies.
Karande P; Mitragotri S
Annu Rev Chem Biomol Eng; 2010; 1():175-201. PubMed ID: 22432578
[TBL] [Abstract][Full Text] [Related]
28. Initiation of adaptive immune responses by transcutaneous immunization.
Warger T; Schild H; Rechtsteiner G
Immunol Lett; 2007 Mar; 109(1):13-20. PubMed ID: 17320194
[TBL] [Abstract][Full Text] [Related]
29. Leishmaniasis, contact hypersensitivity and graft-versus-host disease: understanding the role of dendritic cell subsets in balancing skin immunity and tolerance.
Kautz-Neu K; Meyer RG; Clausen BE; von Stebut E
Exp Dermatol; 2010 Aug; 19(8):760-71. PubMed ID: 20590820
[TBL] [Abstract][Full Text] [Related]
30. Current Progress in Particle-Based Systems for Transdermal Vaccine Delivery.
Pielenhofer J; Sohl J; Windbergs M; Langguth P; Radsak MP
Front Immunol; 2020; 11():266. PubMed ID: 32174915
[TBL] [Abstract][Full Text] [Related]
31. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA.
Jakob T; Walker PS; Krieg AM; Udey MC; Vogel JC
J Immunol; 1998 Sep; 161(6):3042-9. PubMed ID: 9743369
[TBL] [Abstract][Full Text] [Related]
32. Animal models for cutaneous vaccine delivery.
Hirschberg HJ; van Riet E; Oosterhoff D; Bouwstra JA; Kersten GF
Eur J Pharm Sci; 2015 Apr; 71():112-22. PubMed ID: 25686596
[TBL] [Abstract][Full Text] [Related]
33. Multistep navigation of Langerhans/dendritic cells in and out of the skin.
Jakob T; Ring J; Udey MC
J Allergy Clin Immunol; 2001 Nov; 108(5):688-96. PubMed ID: 11692090
[TBL] [Abstract][Full Text] [Related]
34. Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells.
Gaffal E; Schweichel D; Tormo D; Steitz J; Lenz J; Basner-Tschakarjan E; Limmer A; Tüting T
Eur J Cell Biol; 2007 Dec; 86(11-12):817-26. PubMed ID: 16928407
[TBL] [Abstract][Full Text] [Related]
35. Transdermal delivery of vaccines - Recent progress and critical issues.
Ita K
Biomed Pharmacother; 2016 Oct; 83():1080-1088. PubMed ID: 27544552
[TBL] [Abstract][Full Text] [Related]
36. Directly transfected langerin+ dermal dendritic cells potentiate CD8+ T cell responses following intradermal plasmid DNA immunization.
Elnekave M; Furmanov K; Nudel I; Arizon M; Clausen BE; Hovav AH
J Immunol; 2010 Sep; 185(6):3463-71. PubMed ID: 20713888
[TBL] [Abstract][Full Text] [Related]
37. [Cutaneous immune system].
Schmitt D
C R Seances Soc Biol Fil; 1994; 188(3):207-21. PubMed ID: 7834504
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous dendritic cells.
Valladeau J; Saeland S
Semin Immunol; 2005 Aug; 17(4):273-83. PubMed ID: 15953735
[TBL] [Abstract][Full Text] [Related]
39. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response.
Strid J; Hourihane J; Kimber I; Callard R; Strobel S
Eur J Immunol; 2004 Aug; 34(8):2100-9. PubMed ID: 15259007
[TBL] [Abstract][Full Text] [Related]
40. Needle-free epidermal powder immunization.
Chen D; Maa YF; Haynes JR
Expert Rev Vaccines; 2002 Oct; 1(3):265-76. PubMed ID: 12901567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
